Biopharmaceutics Group, Global Clinical Management, Dr. Reddy's Laboratories Ltd., Integrated Product Development Organization (IPDO), BachupallyMedchal Malkajgiri District, Hyderabad, Telangana, 500 090, India.
Clinical Pharmacokinetics, Global Clinical Management, Dr. Reddy's Laboratories Ltd., Integrated Product Development Organization (IPDO), BachupallyMedchal Malkajgiri District, Hyderabad, Telangana, 500 090, India.
AAPS PharmSciTech. 2024 Aug 21;25(7):193. doi: 10.1208/s12249-024-02904-9.
Physiologically based pharmacokinetic (PBPK) or physiologically based biopharmaceutics models (PBBM) demonstrated plethora of applications in both new drugs and generic product development. Justification of dissolution specifications and establishment of dissolution safe space is an important application of such modeling approaches. In case of molecules exhibiting saturable absorption behavior, justification of dissolution specifications requires development of a model that incorporates effects of transporters is critical to simulate in vivo scenario. In the present case, we have developed a semi-mechanistic PBBM to describe the non-linearity of BCS class III molecule metformin for justification of dissolution specifications of extended release formulation at strengths 500 mg and 1000 mg. Semi-mechanistic PBBM was built using physicochemical properties, dissolution and non-linearity was accounted through incorporation of multiple transporter kinetics at absorption level. The model was extensively validated using literature reported intravenous, oral (immediate & extended release) formulations and further validated using in-house bioequivalence data in fasting and fed conditions. Virtual dissolution profiles at lower and upper specifications were generated to justify the dissolution specifications. The model predicted literature as well as in-house clinical study data with acceptable prediction errors. Further, virtual bioequivalence trials predicted the bioequivalence outcome that matched with clinical study data. The model predicted bioequivalence when lower and upper specifications were compared against pivotal test formulations thereby justifying dissolution specifications. Overall, complex and saturable absorption pathway of metformin was successfully simulated and this work resulted in regulatory acceptance of dissolution specifications which has ability to reduce multiple dissolution testing.
基于生理学的药代动力学(PBPK)或基于生理学的生物药剂学模型(PBBM)在新药和仿制药开发中都有广泛的应用。验证溶出度规格并建立溶出度安全区间是此类建模方法的重要应用。对于表现出饱和吸收行为的分子,验证溶出度规格需要开发一种模型,该模型必须纳入转运体的影响,以模拟体内情况。在本案例中,我们开发了一种半机械性 PBBM 来描述 BCS 分类 III 分子二甲双胍的非线性,以验证 500mg 和 1000mg 缓释制剂的溶出度规格。半机械性 PBBM 是基于理化性质构建的,通过在吸收水平上纳入多种转运体动力学来解释非线性。该模型通过使用文献报道的静脉内、口服(即时和缓释)制剂进行了广泛验证,并通过在禁食和进食条件下使用内部生物等效性数据进行了进一步验证。生成较低和较高规格的虚拟溶出曲线以验证溶出度规格。该模型预测了文献和内部临床研究数据,预测误差在可接受范围内。此外,虚拟生物等效性试验预测了与临床研究数据相符的生物等效性结果。当将较低和较高规格与关键试验制剂进行比较时,该模型预测了生物等效性,从而验证了溶出度规格。总的来说,成功模拟了二甲双胍复杂且饱和的吸收途径,这一工作使溶出度规格得到了监管部门的认可,从而减少了多次溶出度测试。